# Binghe Xu

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/binghe-xu/

## Facts

| Field | Value |
| --- | --- |
| Citations | 29,422 |
| Field | Advanced Breast Cancer Therapies |
| h-index | 63 |
| i10-index | 243 |
| Last Known Institution | Chinese Academy of Medical Sciences & Peking Union Medical College |
| OpenAlex ID | https://openalex.org/A5008098651 |
| ORCID iD | https://orcid.org/0000-0003-4195-337X |
| Works | 550 |

## Researcher papers

- [Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer](https://scholariq.org/papers/trastuzumab-deruxtecan-in-previously-treated-her2-low-advanced-breast-cancer/)
- [3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)](https://scholariq.org/papers/3rd-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-3/)
- [5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)](https://scholariq.org/papers/5th-eso-esmo-international-consensus-guidelines-for-advanced-breast-cancer-abc-5/)
- [De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017](https://scholariq.org/papers/de-escalating-and-escalating-treatments-for-early-stage-breast-cancer-the-st/)
- [Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer](https://scholariq.org/papers/primary-results-from-impassion131-a-double-blind-placebo-controlled-randomised/)
- [Abstract of papers](https://scholariq.org/papers/abstract-of-papers/)
- [Pyrotinib plus capecitabine versus lapatinib plus capecitabine for the treatment of HER2-positive metastatic breast cancer (PHOEBE): a multicentre, open-label, randomised, controlled, phase 3 trial](https://scholariq.org/papers/pyrotinib-plus-capecitabine-versus-lapatinib-plus-capecitabine-for-the-treatment/)
- [Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37 298 women with early breast cancer in 26 randomised trials](https://scholariq.org/papers/increasing-the-dose-intensity-of-chemotherapy-by-more-frequent-administration-or/)
- [Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer](https://scholariq.org/papers/phase-i-study-and-biomarker-analysis-of-pyrotinib-a-novel-irreversible-pan-erbb/)
- [Adjuvant Capecitabine With Docetaxel and Cyclophosphamide Plus Epirubicin for Triple-Negative Breast Cancer (CBCSG010): An Open-Label, Randomized, Multicenter, Phase III Trial](https://scholariq.org/papers/adjuvant-capecitabine-with-docetaxel-and-cyclophosphamide-plus-epirubicin-for/)

## Researcher topics

- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Breast Cancer Treatment Studies](https://scholariq.org/topics/breast-cancer-treatment-studies/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)

## Researcher university

- [Chinese Academy of Medical Sciences & Peking Union Medical College](https://scholariq.org/institutions/chinese-academy-of-medical-sciences-and-peking-union-medical-college/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.